Opko buys up cancer diagnostics player Bio-Reference in $1.47B deal

Diagnostics player Opko Health is buying Bio-Reference Laboratories for 2.75 shares of its stock for every share of Bio-Reference. The deal values Bio-Reference at $1.47 billion, according to Opko, which plans to amp up sales of the 4Kscore test, a blood test that provides a patient's specific personalized risk score for aggressive prostate cancer. Opko's stock dropped 7% on the news. The deal is expected to close in the second half of this year. Release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.